STTR Phase II: Dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images

STTR II 期：通过高分辨率全身图像对可疑色素性皮肤病变进行皮肤科医生级别的检测

• 批准号: 2335086
• 负责人: Davood Tashayyod
• 金额: $ 99.64万
• 依托单位: LUMO IMAGING LLC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2335086&HistoricalAwards=false
• 关键词: STTR; Phase; II; Dermatologist; level

This Small Business Technology Transfer (STTR) Phase II project includes early detection of skin cancers, resulting in better outcomes and a reduction in mortality and healthcare expenditures. Each year in the United States, nearly 5 million people are treated for skin cancer, with an annual cost estimated at $8.1 billion. Annual productivity losses are estimated to cost an additional $4.5 billion. There is a considerable health disparity in the diagnosis of skin cancer within the U.S.; The average wait time to see a dermatologist is currently 32.3 days but it varies greatly by location. Early detection reduces disfigurement by reducing the size and extent of surgical removal and reducing the side effects that late-stage patients experience from systemic therapies. Furthermore, the project increases the economic competitiveness of the U.S. This Small Business Technology Transfer (STTR) Phase II project is to productize a novel, pigmented, lesion analysis system for wide field-of-view images. The product will be built on a previously developed total body photography system and proof of concept lesion classification software as a medical device that was developed in Phase I. The dermatoscope-like resolution provides a solid foundation for a system that can automatically (without the involvement of a dermatologist) detect and classify various skin conditions in a clinical setting and/or a radiology center (similar to how mammograms are done). Skin cancers, including both melanomas and non-melanomas, are the most common types of cancer in the United States. Early-stage identification of suspicious pigmented lesions in primary care settings can lead to improved melanoma prognosis and a possible 20-fold reductions in treatment cost. This technology provides the healthcare system with a highly sensitive, specific, and economical means of providing annual skin cancer screening to all at risk individuals.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让 (STTR) 第二阶段项目包括皮肤癌的早期检测，从而带来更好的结果并降低死亡率和医疗支出。在美国，每年有近 500 万人接受皮肤癌治疗，每年的费用估计为 81 亿美元。据估计，每年生产力损失将额外造成 45 亿美元的损失。在美国，皮肤癌的诊断存在相当大的健康差异；目前看皮肤科医生的平均等待时间为 32.3 天，但不同地点的等待时间差异很大。早期检测通过减少手术切除的大小和范围以及减少晚期患者因全身治疗而经历的副作用来减少毁容。此外，该项目还提高了美国的经济竞争力。这个小企业技术转让 (STTR) 第二阶段项目旨在生产一种用于宽视场图像的新型色素病变分析系统。该产品将建立在先前开发的全身摄影系统和概念验证病变分类软件的基础上，作为一期开发的医疗设备。类似皮肤镜的分辨率为系统提供了坚实的基础，可以自动（无需参与）皮肤科医生）在临床环境和/或放射中心检测和分类各种皮肤状况（类似于乳房 X 光检查的方式）。皮肤癌，包括黑色素瘤和非黑色素瘤，是美国最常见的癌症类型。在初级保健机构中早期识别可疑色素病变可以改善黑色素瘤预后，并可能将治疗成本降低 20 倍。该技术为医疗保健系统提供了一种高度敏感、具体且经济的方式，为所有高危人群提供年度皮肤癌筛查。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优势和更广泛的评估进行评估，被认为值得支持。影响审查标准。